Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study

Table 4 Systemic and ocular adverse events

	Treatment group (sirolimus + aflibercept)	Control group (aflibercept monotherapy)
Systemic events
Serious adverse events	3^a	0
Minor adverse events	4	2
Ocular events
Serious adverse events	0	0
Minor adverse events	4	2

This table lists the number of adverse events in each group, separated into systemic and ocular adverse events
^a Hospitalizations due to pancreatitis, pneumonia, and worsening hypertension. All serious adverse events resolved without sequelae

ISSN: 2056-9920